Enhanced Immunoprotective Effects by Anti-IL-17 Antibody Translates to Improved Skeletal Parameters Under Estrogen Deficiency Compared With Anti-RANKL and Anti-TNF-α Antibodies
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Activated T cell has a key role in the interaction between bone and immune system. T cells produce proinflammatory cytokines, including receptor activator of NF-κB ligand (RANKL), tumor necrosis factor α (TNF-α), and interleukin 17 (IL-17), all of which augment osteoclastogenesis. RANKL and TNF-α are targeted by inhibitors such as denosumab, a human monoclonal RANKL antibody, and infliximab, which neutralizes TNF-α. IL-17 is also an important mediator of bone loss, and an antibody against IL-17 is undergoing phase II clinical trial for rheumatoid arthritis. Although there are a few studies showing suppression of Th17 cell differentiation and induction of regulatory T cells (Tregs) by infliximab, the effect of denosumab remains poorly understood. In this study, we investigated the effects of anti-TNF-α, anti-RANKL, or anti-IL-17 antibody administration to estrogen-deficient mice on CD4+ T-cell proliferation, CD28 loss, Th17/Treg balance and B lymphopoesis, and finally, the translation of these immunomodulatory effects on skeletal parameters. Adult Balb/c mice were treated with anti-RANKL/-TNF-α/-IL-17 subcutaneously, twice a week, postovariectomy (Ovx) for 4 weeks. Animals were then autopsied; bone marrow cells were collected for FACS and RNA analysis and serum collected for ELISA. Bones were dissected for static and dynamic histomorphometry studies. We observed that although anti-RANKL and anti-TNF-α therapies had no effect on Ovx-induced CD4+ T-cell proliferation and B lymphopoesis, anti-IL-17 effectively suppressed both events with concomitant reversal of CD28 loss. Anti-IL-17 antibody reduced proinflammatory cytokine production and induced Tregs. All three antibodies restored trabecular microarchitecture with comparable efficacy; however, cortical bone parameters, bone biomechanical properties, and histomorphometry were best preserved by anti-IL-17 antibody, likely attributable to its inhibitory effect on osteoblast apoptosis and increased number of bone lining cells and Wnt10b expression. Based on the superior immunoprotective effects of anti-IL-17, which appears to translate to a better skeletal preservation, we propose beginning clinical trials using a humanized antibody against IL-17 for treatment of postmenopausal osteoporosis. © 2014 American Society for Bone and Mineral Research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pathogenesis of osteoporosis: concepts, conflicts, and prospects
Raisz, L. G. (2005) · Journal of Clinical Investigation · doi:10.1172/jci27071 · Cited by 1,779
Sato, K., Suematsu, A., Okamoto, K., Yamaguchi, A., Morishita, Y., Kadono, Y., Tanaka, S., Kodama, T., Akira, S., Iwakura, Y., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061775 · Cited by 1,554
Interleukin-17 and Type 17 Helper T Cells
Miossec, P., Korn, T., & Kuchroo, V. K. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0707449 · Cited by 1,409 · cited 1×
“Phase II trial with an antibody against IL‐17 (AIN457) in RA patients is presently under way.((32)) We have shown that blocking IL‐17 prevented bone loss in estrogen deficiency‐induced osteopenia and increased differentiation of Th17 cells.”
BackgroundTH17 cells in development: an updated view of their molecular identity and genetic programming
Dong, C. (2008) · Nature reviews. Immunology · doi:10.1038/nri2295 · Cited by 1,064 · cited 5×
“As Stat5 is a negative regulator of Th17 and promotes the development of Tregs,((53)) mRNA levels of Stat 5 were also determined in all three antibody‐treated groups.”
BackgroundInfluentialRoggia, C., Gao, Y., Cenci, S., Weitzmann, M. N., Toraldo, G., Isaia, G., & Pacifici, R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251534698 · Cited by 513 · cited 4×
“Ovx is known to increase the proliferation of proinflammatory T helper cells including CD4þ and CD8þ T cells.((11)) Mice Ovx for 4 weeks have higher frequency of CD4þ T cells in BM compared with the sham group (Fig.”
BackgroundInfluentialOsteoporosis, inflammation and ageing
Ginaldi, L., Di Benedetto, M. C., & De Martinis, M. (2005) · Immunity & Ageing · doi:10.1186/1742-4933-2-14 · Cited by 412 · cited 2×
“Recent studies have established that bone and immune cells are functionally connected because they share the same progenitors and are influenced by the same cytokines.((1,9))”
BackgroundCenci, S., Toraldo, G., Weitzmann, M. N., Roggia, C., Gao, Y., Qian, W. P., Sierra, O., & Pacifici, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533207100 · Cited by 309
The Functional Block of TNF but Not of IL-6 Prevents Bone Loss in Ovariectomized Mice
Kimble, R. B., Bain, S., & Pacifici, R. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.6.935 · Cited by 241 · cited 5×
“0mg/kg anti‐TNF‐a antibody;((15)) Ovxþ 300mg/kg anti‐RANKL antibody;((44)) and Ovxþ 100 ng/kg anti‐IL‐17 antibody twice/week sc.”
BackgroundMethodInfluentialVallejo, A. N., Weyand, C. M., & Goronzy, J. J. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.01.002 · Cited by 223 · cited 1×
“T cells, and decrease of its expression serves as a surrogate of T‐cell senescence.((12,49)) CD4þCD28þ T‐cell population in BM of the Ovx group was dramatically reduced compared with the sham group (p< 0.”
ResultFuruya, Y., Inagaki, A., Khan, M., Mori, K., Penninger, J. M., Nakamura, M., Udagawa, N., Aoki, K., Ohya, K., Uchida, K., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.426080 · Cited by 77 · cited 1×
“Systemic levels of RANKL, TNF‐a, and IL‐17 are enhanced after ovariectomy (Ovx), and their inhibition/functional block is likely to afford effective skeletal protection post‐Ovx.((15,16)) Indeed, neutralizing RANKL action by denosumab has been approved by the FDA for postmenopausal women who are at high risk of osteop…”
BackgroundSelf-citationTarjanyi, O., Boldizsar, F., Nemeth, P., Mikecz, K., & Glant, T. T. (2009) · Immunity & Ageing · doi:10.1186/1742-4933-6-8 · Cited by 32
Cited by
Interaction between bone and immune cells: Implications for postmenopausal osteoporosis
Fischer, V., & Haffner-Luntzer, M. (2022) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2021.05.014 · Cited by 759
Sex steroid deficiency-associated bone loss is microbiota dependent and prevented by probiotics
Li, J.-Y., Chassaing, B., Tyagi, A. M., Vaccaro, C., Luo, T., Adams, J., Darby, T. M., Weitzmann, M. N., Mulle, J. G., Gewirtz, A. T., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86062 · Cited by 643
“The importance of IL-17 in bone loss is highlighted by the fact that silencing of IL-17R (72) or treatment with an anti–IL-17 antibody (73) prevent ovx-induced bone loss.”
Self-citationThe effect of cytokines on osteoblasts and osteoclasts in bone remodeling in osteoporosis: a review
Xu, J., Yu, L., Liu, F., Wan, L., & Deng, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1222129 · Cited by 263
Li, L., Rao, S., Cheng, Y., Zhuo, X., Deng, C., Xu, N., Zhang, H., & Yang, L. (2019) · MicrobiologyOpen · doi:10.1002/mbo3.810 · Cited by 109
“In addition, oral administration of vancomycin can re‐ duce secondary bile acid and worse insulin sensitivity by changing intestinal microbiota (Vrieze et al., 2014).”
BackgroundFrom osteoimmunology to osteomicrobiology: How the microbiota and the immune system regulate bone
Hsu, E., & Pacifici, R. (2018) · Calcified Tissue International · doi:10.1007/s00223-017-0321-0 · Cited by 106
Metadata
- Authors
- Tyagi, A. M., Mansoori, M. N., Srivastava, K., Khan, M. P., Kureel, J., Dixit, M., Shukla, P., Trivedi, R., Chattopadhyay, N., & Singh, D.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-03-28
- Volume
- 29
- Issue
- 9
- Pages
- 1981-1992
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W1707790900
- Cited by
- 120
- References
- 11
- FWCI
- 3.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.